Artificial Blood, also known as synthetic blood or blood substitute, is a medical innovation designed to mimic key functions of human blood, especially oxygen transport. With India's challenges in blood donation, emergency trauma, and remote healthcare, artificial blood becomes an important topic for UPSC Science & Technology, Health Infrastructure, and GS Paper III.
Why is Artificial Blood Important?
-
Overcomes blood donation shortages
-
No need for blood group matching
-
Reduced risk of blood-borne infections (HIV, Hepatitis)
-
Can be stored longer and transported easily
-
Useful in:
-
Rural health services
-
Disaster management
-
Military and border areas
-
Pandemic emergency care
-
Types of Artificial Blood
1. Hemoglobin-Based Oxygen Carriers (HBOCs)
These use purified hemoglobin (animal or human) to transport oxygen.
a) Hemopure (Bovine Hemoglobin)
-
Source: Cow-derived hemoglobin
-
Used in South Africa (approved), USA (veterinary use)
-
Long shelf life: 3 years
-
No blood group required
-
Limitation: Can cause oxidative stress
b) PolyHeme (Human Hemoglobin)
-
Made from expired human blood
-
Tested for trauma cases and blood loss
-
Faced FDA trial failure over cardiac side effects
-
No longer in production
2. Perfluorocarbon-Based Oxygen Carriers (PFCs)
These are synthetic chemicals that dissolve and carry oxygen.
Fluosol-DA
-
First FDA-approved artificial blood (1989)
-
Required oxygen-rich environments (60%)
-
Used for organ preservation and cardiac surgery
-
Withdrawn due to side effects and poor performance
Comparison Table
| Feature | Hemopure | PolyHeme | Fluosol-DA |
|---|---|---|---|
| Type | HBOC | HBOC | PFC |
| Source | Cow hemoglobin | Human hemoglobin | Synthetic chemicals |
| Blood Matching | Not needed | Not needed | Not needed |
| Storage Life | Up to 3 years | Few months | Few months |
| Approval | Limited countries | Not approved | Withdrawn |
Artificial Blood: Relevance in India & Current Affairs (2024–25)
-
2024: DRDO & AIIMS initiated clinical research for India's first synthetic blood substitute
-
Global: Japan and South Korea are testing oxygen nanocarriers for emergency medicine
-
WHO's 2024 report highlighted blood innovation for LMICs (like India)
UPSC Link: Connect with Ayushman Bharat, Atmanirbhar Bharat in Biotech, and National Disaster Response Framework.
Applications in Indian Context
-
Emergency trauma centers with low donor stock
-
Military & Naxal-affected areas
-
Natural disasters (e.g., floods, quakes)
-
Remote tribal or Himalayan regions
-
Religious beliefs forbidding blood transfusion
Challenges in Artificial Blood Development
-
Toxicity risks in clinical trials
-
No immune or clotting function like natural blood
-
High cost of production and low market availability
-
Ethical and regulatory roadblocks
FAQs – Artificial Blood for UPSC
Q1: Is artificial blood available in India?
Not yet commercially. Indian trials are in the early research phase.
Q2: Can artificial blood fully replace human blood?
Not fully. It mimics oxygen transport, but not immunity or clotting.
Q3: What is Hemopure?
An HBOC derived from cow hemoglobin, approved for limited use.
Q4: Why did Fluosol-DA fail?
Required high oxygen and had side effects; thus withdrawn.
Q5: What are UPSC topics linked to this?
-
Science & Tech (GS III)
-
Disaster Management
-
Health Infrastructure
-
Innovation & Startups in India
MCQs – UPSC CSE 2025 Practice
1. Hemopure is derived from:
A) Human plasma
B) Cow hemoglobin
C) Synthetic nanobots
D) White blood cells
Ans: B
2. Fluosol-DA was withdrawn mainly due to:
A) High cost
B) Side effects and inefficacy
C) Religious objections
D) Government policy
Ans: B
3. Which one of the following is not an HBOC?
A) Hemopure
B) PolyHeme
C) Fluosol-DA
D) None of the above
Ans: C
4. Which is a challenge in artificial blood development?
A) Shortage of hemoglobin
B) Long shelf life
C) Toxicity and immune issues
D) Excess donor blood
Ans: C
5. Which Indian institution is currently involved in artificial blood R&D?
A) ISRO
B) AIIMS + DRDO
C) CSIR
D) NITI Aayog
Ans: B
Mains Question (GS Paper III – Science & Technology)
Q. “Artificial blood offers a futuristic solution to India’s blood shortage crisis but poses major scientific, ethical, and regulatory challenges.”
Discuss its relevance, recent developments, and policy implications in the Indian context. (250 words)
